

IMMUNOGEN INC  
Form 8-K  
December 17, 2007

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **December 14, 2007**

**ImmunoGen, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other  
jurisdiction of  
incorporation)

**0-17999**  
(Commission File  
Number)

**04-2726691**  
(IRS Employer  
Identification No.)

**128 Sidney Street, Cambridge, MA 02139**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 995-2500**

## Edgar Filing: IMMUNOGEN INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 7.01 REGULATION FD DISCLOSURE**

On December 14, 2007, Genentech, Inc. presented updated Phase I clinical findings on trastuzumab-DM1 (T-DM1) at the 30th Annual San Antonio Breast Cancer Symposium (SABC). T-DM1 is an anticancer compound in development by Genentech that comprises ImmunoGen's cell-killing agent, DM1, linked to Genentech's HER2-targeting antibody, trastuzumab.

The findings reported are from a Phase I clinical trial being conducted by Genentech that evaluates T-DM1 when administered once every three weeks to patients with HER2-positive metastatic breast cancer that has progressed on or within 60 days of receiving a chemotherapy regimen containing trastuzumab (Herceptin®). Twenty-four patients were enrolled in the study presented. Among these, 15 patients received T-DM1 at the maximum tolerated dose as determined in the study (3.6 mg/kg).

The updated findings reported today identify that 12 of the 15 patients receiving 3.6 mg/kg T-DM1 have had a partial response (PR) or stable disease (SD). As previously disclosed, 5 of these 15 patients had a PR. Among the patients who had SD, 5 had SD for a duration ranging from at least 130 days to at least 260 days.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Date: December 14, 2007

/s/ Daniel M. Junius

Daniel M. Junius  
Executive Vice President and Chief Financial Officer